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Abstract
Introduction: Metastasis from primary tumor to the lungs is a major cause of the mortality associated with breast
cancer. Both immune and inflammatory responses impact whether circulating mammary tumor cells successfully
colonize the lungs leading to established metastases. Nuclear factor -kappaB (NF-B) transcription factors regulate
both immune and inflammatory responses mediated in part by the activities of macrophages. Therefore, NF-B
activity specifically within macrophages may be a critical determinant of whether circulating tumor cells
successfully colonize the lungs.
Methods: To investigate NF-B signaling within macrophages during metastasis, we developed novel inducible
transgenic models which target expression of the reverse tetracycline transactivator (rtTA) to macrophages using
the cfms promoter in combination with inducible transgenics that express either an activator (cIKK2) or an inhibitor
(IBa-DN). Doxycyline treatment led to activation or inhibition of NF-B within macrophages. We used a tail vein
metastasis model with mammary tumor cell lines established from MMTV-Polyoma Middle T-Antigen-derived
tumors to investigate the effects of modulating NF-B in macrophages during different temporal windows of the
metastatic process.
Results: We found that activation of NF-B in macrophages during seeding leads to a reduction in lung
metastases. The mechanism involved expression of inflammatory cytokines and reactive oxygen species, leading to
apoptosis of tumor cells and preventing seeding in the lung. Activation of NF-B within macrophages after the
seeding phase has no significant impact on establishment of metastases.
Conclusions: Our results have identified a brief, defined window in which activation of NF-B has significant anti-
metastatic effects and inhibition of NF-B results in a worse outcome.
Introduction
The microenvironment that exists during chronic
inflammation can contribute to cancer progression [1,2].
Therefore, anti-inflammatory strategies are being investi-
gated as potential cancer therapies. However, such
approaches may have undesired effects on host immune
responses. Potentially, these negative effects could be
limited by targeting interventions to specific cell types,
but little is known about the contribution of individual
inflammatory cell types to the progression of cancer.
The transcription factor nuclear factor kappa B (NF-
B) regulates inflammatory status and plays key roles in
immune responses. NF-B is a dimer formed from a
multi-subunit family consisting of p65 (Rel A), Rel B, c-
Rel, p105/p50 (NF-B1), and p100/p52 (NF-B2) [3,4].
In the classical NF-B signaling pathway, the p50/p65
subunits are held in the cytosol by the inhibitory IBa
[5,6]. During activation, IB kinase (IKK) 2 phosphory-
lates IBa leading to ubiquitination and degradation.
P50/p65 then translocates into the nucleus, binds to
consensus DNA sequences activating expression of
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signaling using a constitutive form of IKK2 to activate
or a mutant form of IBa to inhibit NF-B activity
[8-10].
Macrophages are key mediators of the interaction
between inflammation, immunity and cancer. The role
of macrophages in cancer has received attention due to
the discovery of their tumor-promoting effects [11-13].
Efforts have been made to classify macrophages accord-
ing to phenotype. The M1 macrophage phenotype is
associated with production of reactive oxygen species
(ROS), presentation of antigens, release of inflammatory
cytokines and cytotoxic effects on pathogens and tumor
cells. In contrast, the M2 macrophage phenotype has a
reduced ability to present antigens and produce ROS,
expresses scavenger receptors, promotes angiogenesis
and wound healing, and is associated with tumor-pro-
moting effects [14,15]. However, tumor-associated
macrophages (TAMs) can express genes associated with
both the M1 and M2 phenotypes highlighting the need
for further investigation into macrophage phenotype
during tumorigenesis [16].
Recent studies have investigated the role of NF-Bi n
macrophages during tumorigenesis. A LysM-Cre/floxed
IKK2 transgenic, resulting in deletion of IKK2 in cells of
the myeloid lineage (macrophages and granulocytes), led
to a reduction in colon tumor incidence and size in a
colitis-associated cancer model [17]. An IB-super
repressor targeted to Kupffer cells (liver macrophages)
led to a similar reduction in tumor incidence in a mur-
ine model of hepatocellular carcinoma [18]. It has been
reported that TAMs can induce invasive behavior of
ovarian tumor cells via NF-B [19,20]. In established
orthotopic ovarian tumors, the introduction of macro-
phages with inhibited IKK2 led to a reduction in tumor
burden. These effects were associated with a switch
from M2 to M1 phenotype upon NF-B inhibition [21].
These studies suggest a tumor-promoting effect of NF-
B in myeloid cells, including macrophages.
Despite these data pointing to a pro-tumor role for
NF-B in macrophages, genes regulated by NF-B could
also lead to an anti-tumor phenotype, suggesting that
effects may be more complex. We have generated trans-
genic mouse models to modulate NF-B in specific tis-
sues by introducing doxycycline (dox) in drinking water
[ 8 , 1 0 ] .T oi n v e s t i g a t eN F - B signaling within macro-
phages during metastasis we used a bi-transgenic system
in which the colony stimulating factor 1 receptor pro-
moter (cfms) drives the monocyte/macrophage-specific
expression of the reverse tetracycline transactivator
(rtTA). To activate NF-B, the cfms-rtTA mouse was
crossed with a second transgenic in which constitutively
active IKK2 (cIKK2) was controlled by the tet operon
(termed IKFM). To inhibit NF-B, cfms-rtTA is crossed
with a transgenic line in which dominant negative IBa
is controlled by the tet operon (termed DNFM). We
used these models in a mouse mammary tumor cell tail
vein-injection metastasis model that is extensively used
as a methodology to investigate the later stages of the
metastatic process from the point at which circulating
tumor cells are present. We find that activation of NF-
B in macrophages during a short window around the
time of cell injection leads to a reduction in lung metas-
tasis of mammary tumor cells. The mechanism involves
induction of an anti-tumor M1 phenotype that rapidly
clears tumor cells. Two days after injection of tumor
cells this window of opportunity closes and from this
point activation of NF-B no longer exhibits anti-tumor
effects.
Materials and methods
Tumor cells
PyVT R221A and PYG 129 polyoma tumor cells were
isolated from PyVT mammary gland tumors and cul-
tured as previously described [9,22].
Mouse strains
All animal experiments were approved by the Vanderbilt
University Institutional Animal Care and Use Commit-
tee. All mice were on an FVB strain background, except
the TG/CRE/FMR mice, which were mixed background
(C57BL6 and FVB).
To generate the cfms-rtTA transgenic, the 7.2 kb
mouse cfms promoter region was used to drive the
expression of rtTA-M2 [23]. The cfms-rtTA-M2 trans-
genic construct was microinjected into mouse embryo-
nic stem cells by standard methods. Progeny were
screened for incorporation of transgene by southern blot
and founder lines identified. Macrophage specific
expression of rtTA was determined in mice transgenic
for cfms-rtTA, tet-O-Cre and the ROSA26 LSL-lacZ
allele [24]. cfms-rtTA mice were crossed with mice con-
taining the NF-B inhibiting (tet-O)7-IBaDN-Myc-His
construct or the NF-B activating (tet-O) 7-FLAG-
cIKK2 construct [8,10]. Double transgenics were termed
DNFM or IKFM, respectively. Littermates lacking one
or both transgenes were used as controls.
To generate TG/Cre/FMR mice, Tomato Red/GFP
reporter mice [25] were crossed with tet-O-Cre trans-
g e n i cm i c e[ 2 6 ] .D o u b l et r a n s g e n i cp r o g e n yw e r et h e n
crossed with cfms-rtTA mice to produce triple trans-
genic offspring containing all three transgenes. Litter-
mates lacking the tet-O-Cre were used as controls.
Tail vein metastasis model
To induce transgene expression mice were treated with
2g / Ld o x( S i g m a ,S tL o u i s ,M O ,U S A )i nd r i n k i n g
water. Sucrose (5%) was added to decrease the bitter
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light-induced degradation and water was replaced twice
weekly. For metastasis studies, 1 × 10
6 polyoma tumor
cells (PyVT R221A or PYG 129) in PBS were injected
via the tail vein. Mice were treated with dox either one
week prior to cells until sacrifice, one week prior to
cells until two days post injection, or two days post
injection of cells until time of sacrifice. Mice were sacri-
ficed at two weeks (PyVT R221A) or five weeks
(PYG129) post cell injection for surface lung tumor
quantification. Mouse lungs were inflated with Bouin’s
f i x a t i v e( R I C C AC h e m i c a l ,A r l i n g t o n ,T X ,U S A ) .A f t e r
24 hours of fixation, surface lung tumors were counted.
For seeding studies, mice were treated with dox for
one week then 1 × 10
6 PyVT R221A tumor cells were
injected via the tail vein. Mice were sacrificed one or six
hours post cell injection and lungs harvested for real-
time PCR and western blot analysis.
RNA isolation and RT-PCR
Tissue was homogenized in Trizol (Invitrogen, Carlsbad,
CA, USA) at sacrifice. For characterization, IKFM mice
and controls were treated with dox for one week fol-
lowed by intraperitoneal injection of 1.5 ml of 4% thio-
glycolate in PBS. At sacrifice, three days post injection,
the peritoneal cavity was lavaged with PBS and cells
pelleted.
RNA isolation and reverse transcription reactions were
performed as described [10] for all studies. For studies
utilizing real-time PCR analysis, an Applied Biosystems
Stepone Plus Real-Time PCR system and SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA,
USA) were used. Primers: polyoma middle T [27], TNF-
a [ 1 0 ] ,C X C L 9 :F O R5 ’ GTGGTGAAATAAAAAGAT-
CAGGGC 3’, REV 5’ AAGAGAGAAATGGGTTCCCTG
3’; CCL3: FOR 5’ TGCCCTTGCTGTTCTTCTCT 3’,
REV 5’ GATGAATTGGCGTGGAATCT 3’; mannose
receptor: FOR 5’ CAAGGAAGGTTGGCATTTGT 3’,
REV 5’ CCTTTCAGTCCTTTGCAAGC 3’; arginase-1:
FOR 5’ ATGGAAGAGACCTTCAGCTAC 3’,R E V5 ’
GCTGTCTTCCCAAGAGTTGGG 3’;G A P D H :F O R5 ’
TGAGGACCAGGTTGTCTCCT 3’,R E V5 ’ CCCTGTT
GCTGTAGCCGTAT 3’.
Bone marrow derived macrophages
IKFM and DNFM mice were treated with dox (2 g/L)
for one week and bone marrow-derived macrophages
(BMDMs) isolated as described [28]. BMDMs were trea-
ted with dox (1 μg/ml) for 16 hours. RNA was isolated
as above, and RT-PCR was completed with the following
primers: IKK: FOR 5’ GGAGCTCCACCGCGGTGCGG
3’,R E V5 ’ TCAGGGACATCTCGGGCAGC 3’, and DN:
FOR 5’ CCTGGCTGTTGTCGAATACC-3’,R E V5 ’
GGTGATGGTGATGATGACCGG 3’.B M D M sw e r e
grown on microscope slides and treated with dox as
above. Cells were fixed in 3% paraformaldehyde and
stained for F4-80 (Invitrogen, Carlsbad, CA, USA), with
DAPI (Sigma, St Louis, MO, USA).
Western blotting
Whole cell lung extracts were prepared and western blot
performed as previously described [10]. Antibody:
Cleaved-Caspase-3 (Cell Signaling Technology, Beverly,
MA, USA).
Luminol imaging
Mice were treated with dox (2 g/L) for one week. L-012
(1.25 mg in 100 μlP B S ,W a k oC h e m i c a l s ,R i c h m o n d ,
VA, USA) was intravenously injected into anesthetized
mice. Mice were imaged with an intensified charge-
coupled device camera (IVIS 200; Xenogen, Hopkinton,
MA, USA). Light emission was detected as photon
counts and analyzed by defining a standard area over
the chest and determining total integrated photon inten-
sity (Living Image software; Xenogen, Hopkinton, MA,
USA).
Flow cytometry
Mice were sacrificed, lungs perfused with cold PBS,
minced and incubated in RPMI media containing 0.7
mg/ml collagenase XI (Sigma, St Louis, MO, USA) and
30 μg/ml DNAse I (Sigma, St Louis, MO, USA) for 40
minutes at 37°C. Digests were strained through a 70
micron filter. Cells were pelleted and treated with 1 ml
red blood cell (RBC) lysis buffer (ACK buffer), washed,
and re-suspended in PBS. Cells were blocked with anti-
mouse CD16/CD32 antibody (eBioscience, San Diego,
CA, USA) before staining with anti-mouse antibodies:
CD45 (30-F11), Gr-1 (Ly-6G), CD11b (M1/70), CD11c
(N418), and CD19 (all eBioscience, San Diego, CA,
USA); F4/80 and B220 (Invitrogen, Carlsbad, CA, USA);
CD4 and NK1.1 (BD Pharmingen, San Diego, CA, USA).
Analysis was performed on an LSRII cytometer with
DIVA software (BD Biosciences, Franklin Lakes, NJ,
USA).
CD11b positive cell isolation
Mice were treated with dox (2 g/L) for one week prior
to sacrifice. Lungs were digested as described above.
Cell suspensions were incubated with MACS CDllb
MicroBeads (Miltenyi Biotec, Auburn, CA, USA) and
separated by positive selection using MS columns.
Immunofluorescence
For whole lung tissue staining of IKFM and control
mice, lungs were first perfused with PBS, then inflated
and fixed in formalin overnight followed by paraffin
embedding and sectioning. For cytospin staining, lungs
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above. Cells were spun onto microscope slides then
fixed in 3% paraformaldehyde. Antigen was unmasked
by the sodium citrate method. Primary antibody: NF-B
phospho-p65 (Ser536) (Cell Signaling Technology, Bev-
erly, MA, USA). Secondary antibody: goat anti-rabbit
Alexa Fluor 594 (Invitrogen, Carlsbad, CA, USA). DAPI
(Sigma, St Louis, MO, USA) was used for nuclei stain-
ing. Staining was visualized by Zeiss microscope and
analyzed by MetaMorph software (Molecular Devices,
Sunnyvale, CA).
TG/Cre/FMR lungs were perfused with cold PBS and
then inflated and fixed for four to six hours in 4% paraf-
ormaldehyde before being paraffin embedded and sec-
tioned. DAPI (Sigma, St Louis, MO, USA) counterstain
was used as above.
Statistical analyses
Statistical analyses were performed using Graph Pad
Prism (GraphPad Software Inc., La Jolla, CA, USA). All
data are plotted graphically with vertical bars represent-
ing standard error. Unpaired Student’s t test was used
to assess differences between experimental conditions. A
probability (P) value of less than 0.05 was taken as an
appropriate level of significance.
Results
Characterization of a novel transgenic model to activate
or inhibit NF-B activity in macrophages
To activate or inhibit NF-B signaling in macrophages
we used pairs of transgenics and the tet-on system. The
first transgenic contains the colony stimulating factor
receptor 1 promoter-reverse tetracycline transactivator
(cfms-rtTA) leading to rtTA protein expression in
macrophages. To generate IKFM mice, the cfms-rtTA is
crossed with a transgenic containing the tet operon pro-
moter element upstream of a FLAG-tagged cIKK2 gene.
For DNFM mice, the cfms-rtTA is crossed with a trans-
genic containing the tet operon promoter element
upstream of a myc-tagged dominant negative IBa
(DN-IBa) gene [8-10]. Treatment of IKFM or DNFM
with dox results in expression of transgene in macro-
phages. Littermates lacking one or both transgenes were
used as controls.
BMDMs were cultured from IKFM or DNFM mice
and controls. Immunohistochemistry for the macro-
phage-specific marker F4/80 (Figure 1a, part i) and flow
cytometry for both F4/80 and CD11b (Figure 1a, part ii)
confirmed that the cells were macrophages. Cells were
treated with dox (1 μg/ml) for 24 hours, RNA isolated
and RT-PCR performed for the expression of cIKK2
mRNA or DN-IBa mRNA. cIKK2 expression was
observed in IKFM macrophages and DN-IBa was
observed in DNFM macrophages, with no transgene
expression observed in controls (Figure 1a, part iii). Pri-
mers were designed such that the reverse primer was in
the FLAG sequence (cIKK2) or myc sequence (DN-
IBa), ensuring specificity for transgene expression.
To test in vivo expression of transgenes in macro-
phages, IKFM or control mice were treated with dox (2
g/L) for one week. Thioglycolate-elicited peritoneal
macrophages were isolated and RT-PCR performed for
cIKK2 transgene expression. Transgene mRNA was
expressed in IKFM macrophages but not in controls
(Figure 1b). To further characterize transgene expression
in vivo, IKFM or control mice were treated with dox (2
g/L) for four weeks. Tissues with high levels of macro-
phages were isolated and RT-PCR performed for expres-
sion of the cIKK2 transgene (Figure 1c). Transgene
expression was observed in tissues from IKFM mice and
was absent in controls. Equivalent characterization was
completed in DNFM peritoneal macrophages and tissues
that also demonstrated macrophage-targeted, inducible
DN transgene expression.
To further determine both the macrophage cell speci-
ficity and the activity associated with the transgene
expression, we utilized several methods. First, lungs
from IKFM mice or controls treated with dox for one
week were homogenized and CD11b-positive and nega-
tive cells were separated. Using RT-PCR, cIKK2 expres-
sion was observed in CD11b-positive cells from the
lungs of IKFM mice but not in CD11b-positive cells
from control mice or in CD11b-negative cells from
IKFM mice (Figure 1d). Furthermore, equal numbers of
CD11b-positive cell populations from IKFM or control
lungs were spun onto microscope slides and then
stained and analyzed for nuclear phospho-p65 (Ser536).
The CD11b-positive cells isolated from IKFM lungs
showed an almost eight fold increase in the number of
phospho-p65-positive macrophages vs. the number of
positive macrophages in control CD11b-positive cells
(7.74 ± 0.95 fold increase, n = 4 control and n =4
IKFM, P = 0.0028), indicating that cIKK2 transgene
expression is indeed increasing NF-B signaling.
To confirm the effect of the transgene on NF-Bs i g -
naling in vivo, IKFM mice and controls were tail vein
injected with PyVT R221A polyoma tumor cells. Mice
were treated with dox beginning two days post injection
until the time of sacrifice two weeks later, at which time
all mice had similar lung tumor burden. Paraffin-
embedded tissue was sectioned and stained for phos-
pho-p65 (Ser536) expression as an indicator of NF-B
activation. A subset of macrophages within the IKFM
lungs stained positive for nuclear phospho-p65, whereas
none of these brightly stained macrophages were
observed in control mice (Figure 1e). As an alternative
approach to further confirm the cell specificity of the
cfms-rtTA expression, we utilized a Tomato-Red/green
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Page 4 of 14Figure 1 Characterization of IKFM and DNFM mouse models. (a) Bone marrow-derived macrophages were isolated from IKFM and DNFM
mice and (i) stained for F4/80 via immunofluorescent staining (green = F4/80 and blue = DAPI), (ii) subjected to flow cytometric analysis of F4/
80 and CD11b and (iii) treated with 1 μg/ml doxycycline (dox) for 24 hours in vitro and gene expression analyzed via RT-PCR. (b) Peritoneal
macrophages were isolated from IKFM mice treated with dox (2 g/L) for one week and transgene expression analyzed via RT-PCR. (c) IKFM mice
and controls were treated with dox (2 g/L) for four weeks and transgene expression was detected by RT-PCR in lung, liver, intestines (Int), and
bone marrow (BM). (d) IKFM and control mice were treated with dox (2 g/L) for one week and CD11b positive and negative populations
isolated from lungs for RT-PCR analysis of IKK. GAPDH was performed as control. (e) Phospho-p65 (Ser536) immunofluorescent staining (red =
phospho-p65 and blue = DAPI) of lungs from IKFM and control mice bearing lung metastases and treated with dox (2 g/L). (f) (i) Lung sections
of TG/Cre/FMR mice treated with dox for one week (blue = DAPI) and (ii) flow analysis of TG/Cre/FMR and control lungs. Total cells were first
sorted for CD45 and CD11b double positive cells. This double positive population was then further sorted for Gr-1 and GFP, as shown.
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tet-O-Cre transgenic and the cfms-rtTA mouse. When
treated with dox (2 g/L), triple transgenic mice, termed
TG/Cre/FMR, reveal which cells express the cfms-rtTA,
as the rtTA/Cre combination within these cells flips the
red fluorescence to green GFP. Sections of lung tissue
from TG/Cre/FMR mice on dox for one week confirm
that cells identified by morphology as macrophages are
flipped to green (Figure 1f; no GFP-positive cells were
observed in control littermates that lacked the tet-O-
Cre). Flow cytometry of lungs from TG/Cre/FMR mice
and controls verifies that the GFP-positive cells are
CD45
+CD11b
+ and Gr1
- (Figure 1f). GFP expression
was undetectable in CD45
+ Gr1
+ CD11b
- cells (data not
shown).
Activation of NF-B activity in macrophages leads to a
reduction in tumor burden in a tail vein metastasis model
IKFM mice or controls were treated with dox for one
week before injection of PyVT R221A cells. Dox treat-
ment was continued until lungs were harvested two
weeks post-cell injection. Analysis of surface lung tumor
numbers revealed a significant reduction in lung tumors
in IKFM mice as compared to controls (Figure 2a). The
same experiment was performed in DNFM mice and
controls, but no significant difference in lung tumor
number was observed when NF-Bw a si n h i b i t e d( F i g -
ure 2b).
To investigate modulation of NF-B during later
stages of metastasis, PyVT R221A cells were injected in
the tail vein of IKFM mice and controls and dox treat-
ment was started two days after injection and continued
until collection at two weeks post-injection. No signifi-
cant difference was observed in tumor number between
IKFM mice and controls (Figure 2c) suggesting that the
anti-tumor effect may be an earlier event. Additionally,
DNFM mice were injected with PyVT R221A cells, and
dox treatment was started two days after injection and
continued until sacrifice. Upon collection, DNFM and
control mice showed no significant difference in lung
tumor number (control 67.00 ± 27.08, n =7 ;D N F M
45.44 ± 16.97, n =9 ,P = 0.4924;). Thus, in this model
there is no evidence of a pro-metastatic phenotype
mediated via NF-B activity in macrophages from either
IKFM or DNFM studies in which modulation occurs
from two days post cell injection.
Reduction of lung metastasis by NF-B in macrophages is
an early event
As no effect was observed when dox treatment was
started two days after cell injection, experiments were
performed to look at the impact of NF-B activation in
macrophages in the period immediately surrounding
tumor injection. IKFM mice and controls were treated
with dox for one week before injection of PyVT R221A
cells. Dox treatment was stopped two days post-injec-
tion and lungs were harvested two weeks post-injection.
A significant reduction was observed in the number of
lung tumors in IKFM compared with controls (Figure
3a). To ensure that this was not a cell line-specific
effect, this experiment was repeated with a second, sepa-
rately-derived mammary tumor cell line, PYG 129, that
forms lung tumors five weeks after tail vein injection.
IKFM mice and controls were treated with dox for one
week before injection of PYG 129 cells via the tail vein.
Dox treatment was stopped two days post-injection and
lungs were harvested and surface tumors counted five
weeks post-injection. A significant reduction in lung
tumor formation was observed in IKFM mice as com-
pared with control mice (Figure 3b). This indicates that
the anti-tumor impact of NF-Ba c t i v a t i o ni nm a c r o -
phages occurs in the early stages of lung metastasis
formation.
This experiment was repeated in DNFM mice to
determine impact of NF-B inhibition in macrophages
on the early stages of lung metastasis formation. DNFM
mice and controls were treated with dox for one week
before injection of PyVT R221A cells. Dox treatment
was stopped two days post-cell injection and lungs were
harvested and surface tumors counted two weeks post-
injection. A significant increase in tumor burden was
observed in DNFM mice compared with controls (Fig-
ure 3c) confirming that NF-B activity in macrophages
blocks lung metastasis formation.
Activation of NF-B in macrophages leads to a shift in
macrophage populations in the lung
To assess the environment that the tumor cells
encounter upon being injected into the IKFM mice,
flow cytometric analysis was performed to look at
macrophage populations in IKFM lungs compared with
controls. Mice were treated with dox for one week,
lungs were homogenized and CD45+ (leukocyte mar-
ker), F4/80+ (macrophage marker) cells were selected
for further cell surface marker analysis. Three different
cell populations were analyzed within this group: Gr1
+/CD11b+ reported to represent immature myeloid
cells including myeloid-derived suppressor cells
[29,30], Gr1-/CD11b+ reported to represent newly
recruited/mature macrophages [31] and Gr1-/CD11c+,
which are reported to represent lung resident macro-
phages [32]. Although total F4/80 positive populations
were not significantly different (Control 25.5 ± 13.3,
IKFM 30.9 ± 2.8 n =4 ,P =0 . 4 5 ,p e r c e n t a g e s
expressed out of total CD45
+ cells), a significant
increase in the percentage of Gr1+/CD11b+ as well as
Gr1-/CD11b+ cells was observed in IKFM as compared
with control lungs. A significant decrease in Gr1-/
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ure 4). Thus, activation of NF-B in macrophages cor-
relates with a shift in the macrophage population
surface markers in the lung environment that suggests
a population consisting of immature and recruited/
mature cells with a lower proportion of resident lung
macrophages even in the absence of tumor cells. A
similar change in cell populations was observed in
IKFM mice treated with dox for one week followed by
cell injection and harvest of lungs two days post-injec-
tion. Therefore, this phenotype correlates with both
time points at which a significant reduction in surface
Figure 2 Activation of NF-Bi nm a c r o p h a g e sr e s u l t si nf e w e rl u n gm e t a s t a s e s . IKFM or DNFM mice and controls were treated with
doxycycline (dox; 2 g/L) for one week prior to PyVT cell injection. Dox treatment was continued until sacrifice at two weeks post-injection. (a)
Lung tumor counts in IKFM and control mice (P = 0.0005; n = 11 control, n = 8 IKFM) and representative lung images. (b) Lung tumor counts in
DNFM and control mice (P = 0.7997; n = 6 control, n = 8 DNFM). (c) IKFM mice were injected with PyVT cells. Dox treatment (2 g/L) began two
days post injection and continued until sacrifice at two weeks post cells when surface lung tumors were counted (P = 0.9880; n = 7 control, n =
6 IKFM).
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lar shift in monocyte populations is observed in con-
trol mice, but only after cell injection, whereas the
changes occur in IKFM lungs with dox treatment
alone. This suggests that activating NF-Bi nm a c r o -
phages “pre-educates” the IKFM lung environment to
become anti-tumor, an effect that is achieved in con-
trol mice to a lesser degree only in response to tumor
cells. These differences in macrophage populations
were not observed in IKFM mice compared with con-
trols when cells were injected, dox treatment started
two days post-injection and lungs harvested for
Figure 3 Reduction of lung metastasis by NF-B in macrophages is an early event. IKFM or DNFM mice and controls were treated with
doxycycline (dox; 2 g/L) for one week prior to cell injection. Dox treatment ended two days post cell injection and mice were sacrificed at two
weeks post cells (PyVT R221A) or five weeks post cells (PYG 129). (a) Lung tumor counts in IKFM injected with PyVT R221A cells (P < 0.0001; n =
10 control, n = 7 IKFM) and representative lung images. (b) Lung tumor counts in IKFM injected with PYG 129 cells (P = 0.0270; n = 9 control, n
= 8 IKFM). (c) Lung tumor counts in DNFM injected with PyVT R221A cells (P = 0.0039; n = 6 control, n = 9 DNFM).
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Page 8 of 14Figure 4 Activation of NF-B in macrophages leads to a shift in macrophage populations in the lung. Flow cytometric analysis of
dissociated lung cells from IKFM and control mice. Three treatment groups (all 2 g/L doxycycline (dox)): one week dox - mice were on dox for
one week (control n = 4, IKFM n = 4); two days dox - mice were on dox for one week, PyVT R221A cells were injected via tail vein, dox
treatment was stopped two days after injection and mice sacrificed (control n = 3, IKFM n = 4); two weeks dox - mice were injected with PyVT
cells via tail vein, two days later mice were put on dox and two weeks after cell injection mice were sacrificed (control n = 3, IKFM n = 3). All
cells were gated for CD45+ and then for F4/80+ cells. (a) Representative flow diagrams of one week dox treatment group. (b) Graphs and (c)
table showing percentage of cell populations that were Gr1+/CD11b+ (black), Gr1-/CD11b+ (grey) and Gr1-/Cd11c+ (white; *P < 0.05, **P < 0.01,
***P < 0.001; n ≥ 3 for all groups).
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Page 9 of 14analysis two weeks post-injection, correlating with the
lack of effect on lung tumor number. Analysis of mar-
kers of other immune cell types within the lungs after
one week of dox treatment indicates that the percen-
tages of CD4
+ T cells and B220
+/CD19
+ B cells are
decreased in IKFM whereas the NK1.1
+ natural killer
cell population is increased (CD4
+ T cells: control =
39.3 ± 2.6 and IKFM = 22.4 ± 0.7, P = 0.0001; B220
+/CD19
+ B cells: control = 15.1 ± 1.5 and IKFM = 10.1
±1 . 0 ,P = 0.0123; NK1.1
+ natural killer cells: control =
2 . 9±0 . 4a n dI K F M=5 . 6±0 . 5 ,P = 0.0024; n =6c o n -
trol, n = 8 IKFM for all markers and values expressed
as percentage of CD45
+ cells). These changes are again
suggestive of a pre-activated innate immune response
that occurs prior to tumor cell injection.
Expression pattern in IKFM lung homogenates suggests
that the majority of macrophages are M1 phenotype
To determine whether this reduction in lung metastases
and alteration in macrophage populations correlated
with a particular macrophage phenotype, quantitative
real-time PCR was performed for M1 and M2 markers.
IKFM and controls were treated with dox for one week
after which total lung RNA was extracted and real-time
PCR performed. An increase was observed in CCL3 and
TNF-a mRNA while a decrease was observed in argi-
nase-1 and mannose receptor mRNA (Figure 5). The
decrease in mannose receptor expression was confirmed
in CD11b-positive cells isolated from IKFM vs. control
lungs, assessed via real-time PCR (n =4c o n t r o l ,n =4
IKFM, P = 0.003). Taken together, this suggests that in
Figure 5 Expression pattern in IKFM lung homogenates suggests that the majority of macrophages are M1 phenotype.R N Aw a s
isolated from whole lung samples of IKFM and control mice treated with doxycycline (dox; 2 g/L) for one week. Quantitative real-time PCR was
performed for (a) CCL3, (b) mannose receptor, (c) arginase-1 and (d) TNF-alpha (P < 0.05, **P < 0.01, ***P < 0.001; n = 5 control, n = 5 IKFM).
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Page 10 of 14the lungs of IKFM mice M1 represents the dominant
macrophage phenotype [33].
A reduction in tumor cell seeding accompanied by an
increase in apoptotic signaling is observed in lungs from
IKFM mice
The effects on seeding of tumor cells after intravenous
injection were investigated. IKFM and controls were
treated with dox for one week before injection of PyVT
R221A cells. Lungs were harvested at one hour and six
hours post-injection and RNA isolated. Quantitative
real-time PCR was performed for the polyoma trans-
gene, which reflects tumor cell levels in the lungs. At
one hour post-injection there was no significant differ-
ence in levels of polyoma mRNA between control and
IKFM (Figure 6a). At six hours post-injection a signifi-
cant reduction in polyoma mRNA was observed in
IKFM lungs compared with control (Figure 6b). This
suggests that there were less PyVT R221A cells in IKFM
lungs than control at this point, perhaps due to an
increased level of clearance, which would correlate with
a lack of tumor formation in these mice.
T oi n v e s t i g a t ew h e t h e rt h ee n v i r o n m e n ti nI K F M
lungs increased apoptosis of PyVT R221A cells, western
blot for activated caspase 3 was performed in whole
lung homogenates. Caspase 3 activation was undetect-
able in the lungs of IKFM mice treated with dox for one
week. However, a higher level of caspase 3 activation
was observed in lungs from IKFM mice (Figure 6c) at
six hours post cell injection indicating increased levels
of apoptosis. This suggests that activation of NF-B
does not result in significant cell death in the absence of
injected tumor cells and implies that the apoptosis
occurs in the tumor cells as opposed to the lung
epithelium.
Increased clearing of tumor cells and apoptosis in IKFM
lungs correlates with higher ROS levels and increased
CXCL9 expression
As an increased clearance of tumor cells had been
observed, we were interested in the mechanism contri-
buting to cytotoxic effects. Therefore, we investigated
whether there was a change in levels of ROS. IKFM
mice and controls were treated with dox for one week
and then injected with the L-012 luminol derivative to
allow in vivo imaging of ROS levels over the chest area.
IKFM mice showed a significant increase in ROS levels
as compared with controls (Figure 6d). This suggests
that the lung environment in IKFM mice was more
cytotoxic to tumor cells correlating with increased clear-
ance and a reduction in final tumor counts.
To further investigate the lung microenvironment at
the time of tumor injection, cytokine profiling of bron-
chial alveolar lavage (BAL) fluid from IKFM mice and
controls after one week of dox treatment was performed
using the R&D Systems Proteome Profiler mouse cyto-
kine panel array kit. The only significant difference
detected was an increase in levels of CXCL9 (monokine
induced by gamma interferon) in the IKFM fluid (data
not shown). To confirm this change, real-time PCR was
performed on lung mRNA from the same time point.
There was a significant increase in expression levels of
CXCL9 (Figure 6e), which correlates with an anti-tumor
environment [34].
Discussion
We generated a transgenic mouse model to investigate
t h er o l eo fc l a s s i c a lN F - B signaling in macrophages
during tumorigenesis. We show that activation of NF-
B in macrophages in a mammary tumor tail vein
metastasis model leads to a reduction in lung tumor for-
mation with effects observed only when NF-B is modu-
lated prior to tumor cell introduction during the early
seeding phase. Investigations into the lung phenotype
associated with this effect show that activation of NF-B
leads to a shift in macrophage populations in the lung
with a higher percentage of cells that are Gr1+/Cd11b+
and Gr1-/CD11b+ and a lower percentage of Gr1-/
Cd11c+ cells. This shift in macrophage population and
reduction in lung tumor numbers occurs in lungs that
express increased levels of markers of the M1 anti-
tumor macrophage phenotype. In agreement with this,
we see a decrease in mammary tumor cell seeding fol-
lowing cell injection, an increase in apoptosis and
enhanced formation of ROS and the cytokine CXCL9.
Our data suggest that activation of NF-B in macro-
phages within the lung during the seeding of lung
metastases has an anti-tumor effect.
Our data are in contrast with other in vivo studies
highlighting a tumor-promoting role for macrophages
[17,21]. This may be due to the different murine models
and cancer types and the timing of NF-Ba c t i v a t i o n .
These recently published studies have used the strategy
of Cre-mediated deletion of the IKK2 to inhibit NF-B
signaling in myeloid cells. Our strategy employs specific
activation of the signaling pathway by expression of a
constitutive activator or direct inhibition by expression
of a dominant form of inhibitor, either of which is regu-
lated in an inducible manner. In our model, activation
of NF-B in macrophages before tumor cell arrival gen-
erates a hostile environment for tumor seeding and
growth. This environment is similar to the M1-type
macrophage response seen with a bacterial challenge
[33]. The tail vein metastasis model is inherently an
acute model as mice develop a heavy metastatic load in
the lungs at two weeks and need to be euthanized for
humane reasons. This likely precludes observing the
pro-tumor effects that have been reported in models of
Connelly et al. Breast Cancer Research 2011, 13:R83
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Page 11 of 14Figure 6 A reduction in tumor cell seeding is observed in lungs from IKFM mice. IKFM and control mice were treated with doxycycline
(dox; 2 g/L) for one week before injection of PyVT R221A cells. Lungs were harvested at (a) one hour (n = 5 control, n = 7 IKFM, P = 0.4410)
and (b) six hours (n = 3 control, n = 3 IKFM, P = 0.0214) post injection and RNA isolated from whole lung samples for quantitative real-time PCR
analysis of Polyoma (PYL) expression. (b) Western blot for cleaved caspase-3 on whole cell lung homogenates from mice treated with dox for
one week (no cells injected; n = 4 control and n = 4 IKFM) and homogenates from the six hour time point (n = 4 control and n = 4 IKFM). (c)
IKFM mice and controls were treated with dox for one week and then imaged for ROS (n = 3 control and n = 3 IKFM; P = 0.0011). (e) Real-time
PCR analysis of whole lung RNA for CXCL9 (n = 4 control, n = 3 IKFM, P = 0.0033).
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Page 12 of 14established tumors. Future studies to address effects on
established tumors will need to be performed using
orthotopic models or those in which spontaneous
tumors arise, such as the polyoma transgenic model, to
address this issue.
Recent studies highlight the complexity of NF-Bs i g -
naling during tumorigenesis. Tumor-associated macro-
phages isolated from an orthotopic fibrosarcoma model
show a defective activation of NF-Bi nr e s p o n s et o
lipopolysaccharide [16]. Further investigation reveals
that this lack of activation is due to p50 subunit homo-
dimers and knockout of p50 restores the M1 macro-
phage phenotype and reduces tumor burden [35].
Although this study suggests that defective NF-B acti-
vation within macrophages leads to the development of
an M2, pro-tumor phenotype, others find that NF-kap-
paB signaling, specifically IKK2, is necessary to maintain
the M2 phenotype in an ovarian cancer model [21].
These apparent contradictions were recently reviewed
by Hagemann et. al [36] who propose that NF-Br e g u -
lation of TAMs is both context- and gene-dependent.
IKFM mice showed a significant shift in macrophage
populations when NF-B was activated for one week
before tumors were established. Interestingly, when cells
were analyzed at the third time point (where metastases
a r ee v i d e n t ) ,ad i f f e r e n tpattern of surface marker
expression was observed. This pattern was more similar
to control populations. This agrees with recent reports
showing the plasticity of the macrophage population
during tumorigenesis with a different set of markers
expressed at each stage [37].
The cell marker phenotype in the IKFM mice when an
anti-tumor effect was observed correlates with the
reduction in tumor burden. For example, GR1+/CD11b
+ myeloid cells are a source of ROS, the levels of which
were seen to increase [29]. CXCL9 was significantly up-
regulated in IKFM lungs after one week of dox treat-
ment. NF-B activation leading to CXCL9 production
within macrophages has previously been reported [38].
The injection of a mammary tumor cell line stably
expressing CXCL9 cDNA into mice resulted in smaller
tumors as well as fewer lung metastases. This was found
to be a T-cell-mediated effect, in that the CXCL9 over-
expressing tumors had increased levels of infiltrating
CD4 T cells as compared with vector controls [34].
Although we see increased CXCL9 expression in our
model, we observed a concurrent decrease in CD4 T
cells as assessed by flow cytometry. This could imply a
separate, non-T-cell-mediated, anti-tumor effect asso-
ciated with CXCL9, or suggest that the time points ana-
lyzed were not optimal for analysis of lymphocyte
infiltration. In either case, further investigation into the
role of CXCL9 in this model is required.
Conclusions
We have generated a novel pair of transgenic models
that enable NF-B to be either activated or inhibited in
an inducible manner in macrophages/monocytes by
administration of dox in the drinking water. These mod-
els will enable investigations of the role of NF-B within
macrophages in defined temporal windows within tumor
development and progression and will potentially be of
use for investigations of other disease processes, such as
atherosclerosis. In the current study the models have
been used to investigate the effects of modulation of
NF-B during the seeding phase of metastasis. In con-
trast to what may have been predicted from the cur-
rently available literature, our data show that activation
of NF-B in a short, defined window inhibits metastasis.
In addition, inhibition of NF-B may actually contribute
to increased metastasis. Given the recent interest in
developing NF-B inhibitors for clinical cancer therapy
[39] it is intriguing that, in our study, inhibition of NF-
B within macrophages during metastatic seeding
resulted in a significant increase in lung tumor burden.
This data suggest that inhibition in macrophages during
tumorigenesis at certain time points may interfere with
host-suppressive effects on metastasis formation, and
demonstrates that timing and cell specificity may be the
key determinants of the impact of NF-B inhibitors as a
cancer therapy.
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